%0 Journal Article
%T Effectiveness of Ezetimibe in Reducing the Estimated Risk for Fatal Cardiovascular Events in Hypercholesterolaemic Patients with Inadequate Lipid Control While on Statin Monotherapy as Measured by the SCORE Model
%A John S. Sampalis
%A St¨¦phane Bissonnette
%A Stella Boukas
%J Advances in Preventive Medicine
%D 2011
%I Hindawi Publishing Corporation
%R 10.4061/2011/597163
%X Objectives. The aim of this prospective cohort, multicentre study was to assess the effect of coadministrating ezetimibe 10£¿mg/day with an ongoing statin on the estimated risk for Cardiovascular (CVD) mortality in patients with persistently elevated LDL-C after statin monotherapy. Methods. The Systematic Coronary Risk Evaluation (SCORE) function was used to estimate the 10-year risk for cardiovascular mortality at baseline and 6 weeks. Primary outcome measures were absolute and percent changes in estimated Coronary Heart Disease (CHD) Mortality Risk, and general CVD Mortality Risk (Total CVD Mortality Risk). Results. 825 patients were included in the analysis. Mean (SD) age was 62 (10.5) years and 62.3% were males. The mean (SD) estimated Total CVD Mortality Risk decreased from 0.068 (0.059) at baseline to 0.053 (0.046) at 6 weeks ( ; 95% CI:0.689¨C0.867), while the estimated CHD Mortality Risk decreased from 0.047 (0.040) at baseline to 0.034 (0.029) at 6 weeks ( ; 95% CI:0.624¨C0.826). Conclusions. Co-administration of ezetimibe with a statin is effective in significantly reducing the estimated risk for cardiovascular mortality as measured by the SCORE model. 1. Introduction Cardiovascular disease is the major cause of mortality in Canada, accounting for one-third of all deaths, with an incidence expected to increase within the next decade [1]. Increased serum cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), is directly associated with an increased risk for cardiovascular disease (CVD) [2¨C5]. Initiation of lipid-lowering pharmacologic intervention for the management of hypercholesterolaemia is generally dependent on the individual patient¡¯s estimated risk for cardiovascular events [3, 6, 7]. Ultimately, the aim of lipid-lowering treatment is to effectively reduce the individual patient¡¯s risk for CVD, thus decreasing related mortality, morbidity and burden of illness. A cardiovascular risk prediction model was developed by the SCORE (Systemic COronary Risk Evaluation) project group in accordance to the recommendations from the Second Joint Task Force of European and other Societies on Coronary Prevention [7]. The SCORE model is based on pooled data from 12 European cohort studies, including data on over 205,000 individuals and representing 2.7 million person-years of followup. The model predicts the individual¡¯s 10-year risk for fatal cardiovascular events on the basis of age, gender, smoking status, systolic blood pressure (SBP), and total cholesterol (TC). The total SCORE risk is further subdivided into the risk for fatal CHD and
%U http://www.hindawi.com/journals/apm/2011/597163/